

2023 Antibiogram (January-December)

Gram Negative Organisms ¹															
Legend:	Amikacin	Ampicillin	Amp/sulbactam	Cefazolin ²	Cefoxitin	Ceftazidime	Ceftriaxone	Gentamicin	Meropenem	Pip/Tazobactam	Tobramycin	Trimethoprim/ sulfa	Nitrofurantoin Urinary Tract Infections only	Cefepime	
• Numbers represent % of isolates tested that were susceptible to antibiotic															
• (Total number of isolates)															
↑ ≥ 5% increase in Susceptibility from Previous Year															
↓ ≥ 5% decrease in Susceptibility from Previous Year															
<i>Escherichia coli</i> (1819)	100	60	67	93 ²	94	98	95	94	100	98	94	85	98	-	
<i>Enterobacter</i> species (121)	100	-	-	0	0	87 [↑]	83 [↑]	100	100 ⁵	83 [↑]	98	93	35	100	
<i>Klebsiella</i> species (399)	100	0	81	87 ² ↓	96	94	90	98	100	96	95	90	40	-	
<i>Proteus</i> species (166)	100	78	90	96 ²	96	100	98	95	100 ⁵	100	95	86	0	-	
<i>Pseudomonas aeruginosa</i> (191)	100	-	-	-	-	94	-	- ⁴	91 [↓]	95	99	-	-	93 ³	

Gram Positive Organisms																	
Legend:	Ampicillin	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Oxacillin ⁶	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/ sulfa	Vancomycin	Nitrofurantoin Urinary Tract Infections only	
• Numbers represent % of isolates tested that were susceptible to antibiotic																	
• (Total number of isolates for that organism)																	
↑ ≥ 5% increase in Susceptibility from Previous Year																	
↓ ≥ 5% decrease in Susceptibility from Previous Year																	
Methicillin Susceptible <i>Staphylococcus aureus</i> (407)	-	-	-	82	67	100	94	100	100	0	-	-	92	97	100	22/23 ⁷	
Methicillin Resistant <i>Staphylococcus aureus</i> (251)	-	-	-	78	11	100	61	100	0	0	-	-	90	87	100	14/15 ⁷	
<i>Staphylococcus</i> coagulase negative (207)	-	-	-	66 [↓]	47 [↓]	95	74	100	48 [↓]	0	-	-	83	74 [↓]	100	98	
<i>Enterococcus faecalis</i> (201)	100	-	-	-	-	-	75	98	-	99	-	-	-	-	95	99	
<i>Enterococcus faecium</i> ⁷ (44)	6/44	-	-	-	-	-	5/44	41/44	-	4/44	-	-	-	-	21/44	5/34 ⁷	
<i>Streptococcus pneumoniae</i> ⁷ (29)	-	29/29	27/29	23/29	19/29	-	29/29	29/29	-	-	29/29	22/29	25/29	-	28/28	-	
<i>Streptococcus agalactiae</i> (Group B) ⁷ (26)	24/24	-	-	8/26	8/26	-	26/26	26/26	-	26/26	-	-	-	-	26/26	-	

1. Ciprofloxacin and levofloxacin results not reported for Gram-negative organisms due to discrepancy between susceptibility testing breakpoints and published standards for 2023 testing.
2. Cannot differentiate Cefazolin Susceptible from Intermediate categories by testing method on non-urinary tract specimens. Results valid only when used as therapy for uncomplicated UTI for *Escherichia coli*, *Klebsiella pneumoniae* or *Proteus mirabilis*.
3. Cefepime tested by manual method on *Pseudomonas aeruginosa*.
4. Gentamicin was removed as a suggested treatment option for *Pseudomonas aeruginosa* in the 2023 Clinical and Laboratory Standards Institute M100
5. Meropenem susceptibility testing does not include *Enterobacter aerogenes*, *Enterobacter asburiae*, *Proteus hauserii*, *Proteus penneri*, and *Proteus vulgaris* isolates due to antimicrobial susceptibility testing device limitations.
6. Oxacillin is tested as a surrogate for methicillin and nafcillin.
7. Reported as actual number of isolates susceptible. Trend assessment not provided due to small number of isolates.